Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details) - USD ($) $ in Thousands |
Dec. 31, 2025 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|---|---|---|---|
| Disclosure Of Intangible Assets [Line Items] | |||
| Carrying value of in process research and development | $ 568,800 | $ 571,826 | $ 575,736 |
| In-process research and development acquired | |||
| Disclosure Of Intangible Assets [Line Items] | |||
| Carrying value of in process research and development | 325,081 | 325,081 | $ 427,779 |
| In-process research and development acquired | Cardiovascular products | |||
| Disclosure Of Intangible Assets [Line Items] | |||
| Carrying value of in process research and development | 254,351 | 254,351 | |
| In-process research and development acquired | Intravenous products for metabolic diseases and inflammatory/immunologic conditions | |||
| Disclosure Of Intangible Assets [Line Items] | |||
| Carrying value of in process research and development | $ 70,730 | $ 70,730 |